Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02711553 · ClinicalTrials.gov registry record · Phase 2

A Study of Ramucirumab (LY3009806) or Merestinib (LY2801653) in Advanced or Metastatic Biliary Tract Cancer

A Phase 2 study of Advanced Cancer and Metastatic Cancer, sponsored by Eli Lilly and Company.

Active
Registry status
Phase 2
Development phase
309
Enrollment target
20
Study locations

NCT02711553 is a Phase 2 study of Advanced Cancer and Metastatic Cancer that is active but no longer recruiting, run by Eli Lilly and Company. The registered enrollment target is 309 participants, above the 244-participant average among 122 other Advanced Cancer trials with a reported enrollment target (27% higher). The trial reports 20 study locations across 14 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02711553, a Phase 2 study of Advanced Cancer and Metastatic Cancer, is active but no longer recruiting, sponsored by Eli Lilly and Company.

ACTIVE NOT RECRUITING
Registry status
Phase 2
Development phase
309 participants
Enrollment target
20
Study locations

Study Summary

The main purpose of this study is to evaluate the efficacy and safety of ramucirumab or merestinib or placebo plus cisplatin and gemcitabine in participants with advanced or metastatic biliary tract cancer.

Conditions Studied

Advanced Cancer Metastatic Cancer Biliary Tract Cancer

Interventions

  • DRUG Cisplatin
  • DRUG Gemcitabine
  • DRUG Ramucirumab
  • DRUG Placebo Oral
  • DRUG Merestinib

Study Locations (20)

Missouri

  • Washington University Medical School - City of Saint Peters
  • Washington University Medical School - Creve Coeur
  • Washington University Medical School - St Louis
  • Washington University Medical School - St Louis

Pennsylvania

  • Thomas Jefferson University - Philadelphia
  • Fox Chase Cancer Center - Philadelphia

Tennessee

  • Florida Cancer Specialists - Nashville
  • Tennessee Oncology PLLC - Nashville

Other

  • Fundacion Favaloro - Ciudad de Buenos Aires
  • Fundación CORI para la Investigación y Prevención del Cáncer - La Rioja

Arizona

  • The University of Arizona Cancer Center - Tucson

California

  • UCSF Medical Center at Mission Bay - San Francisco

District of Columbia

  • Georgetown University Medical Center - Washington D.C.

Florida

  • University of Florida School of Medicine - Gainesville

Trial Details

FieldValue
Enrollment Target 309 participants
Start Date 2016-05-19
Est. Completion 2026-12
Phase Phase 2

Sponsor

Eli Lilly and Company

1,341 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT02711553

The ClinicalTrials.gov registry entry for NCT02711553 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 309 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 244-participant average among 122 other Advanced Cancer trials with a reported enrollment target (27% higher). The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with Advanced Cancer appearing as the primary indexed condition, and to 5 interventions - of which Cisplatin is the first listed.

NCT02711553 reports 20 study locations spanning 14 distinct geographic areas - top geographies include Missouri, Pennsylvania, Tennessee.

Frequently Asked Questions

What is clinical trial NCT02711553 about?

NCT02711553 is a clinical study titled "A Study of Ramucirumab (LY3009806) or Merestinib (LY2801653) in Advanced or Metastatic Biliary Tract Cancer". The main purpose of this study is to evaluate the efficacy and safety of ramucirumab or merestinib or placebo plus cisplatin and gemcitabine in participants with advanced or metastatic biliary tract cancer.

What is the current status of trial NCT02711553?

This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 309 participants. The study started on 2016-05-19. Estimated completion is 2026-12.

What conditions does trial NCT02711553 study?

This clinical trial studies the following conditions: Advanced Cancer, Metastatic Cancer, Biliary Tract Cancer.

What interventions are being tested in trial NCT02711553?

The interventions under investigation include: Cisplatin (DRUG), Gemcitabine (DRUG), Ramucirumab (DRUG), Placebo Oral (DRUG), Merestinib (DRUG).

Who is sponsoring clinical trial NCT02711553?

This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02711553 being conducted?

This trial has 20 study locations across Arizona, California, District of Columbia, Florida, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Advanced Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Advanced Cancer

All registered trials for this condition

Metastatic Cancer

All registered trials for this condition

Arizona

All trials with a study site in Arizona

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.